The Sunnyvale, CA-based company has long been the top dog in surgical robotics but increased competition is right around the corner for the firm.
Neovasc said it had resolved the three claims of correction of patent inventorship made by Irvine, CA-based Edwards Lifesciences.
The Abbott Park, IL-based has had a solid foundation of success dating back to the closure of the St. Jude Medical acquisition.
Results from the prospective, randomized, controlled, multi-surgeon clinical trial were published in Ophthalmology Glaucoma.
Johnson & Johnson’s earnings might have been down 14% when compared to last year, but the New Brunswick, NJ-based company was still able to beat analysts’ expectations.
Fe3 Medical completed the first human study of its iontophoretic transdermal technology designed to bypass ionic resistance build up in the skin.
The Lake Oswego, OR-based company received a nod from FDA for the coronary stent system in September of 2018 but launched the device this month to coincide with the release of Orsiro, its ultrathin strut DES.
The move comes about a week after the San Diego-based company revealed it would cut 50% of its workforce.
Solana Beach, CA-based Puregraft has developed a technology that would use a person’s own fat for breast augmentation or restructuring.
The Rolling Stones frontman’s recent procedure has brought a great deal of awareness to the TAVR market, which could be beneficial to device makers in the space.
The Palo Alto, CA-based company has received FDA clearance for a wearable that can remotely monitor patients with chronic diseases, such as chronic obstructive pulmonary disease (COPD), allowing the detection of early signs of deterioration before symptoms are noticeable.
Alcon performed extremely well on the market trading at $57.81 a share, giving the eye-care company a value of nearly $29 billion.